PALO ALTO, Calif., April 19, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it is incorporating new imaging technologiesin the Halcyon™ 2.0 treatment system to expand its capabilities and ability to deliver high quality cancer care globally. First announced in May 2017, Halcyon is revolutionizing the clinical workflow and simplifying
Solidifying Halcyon's reputation of delivering advanced treatments while enhancing patient comfort and increasing ease of use for healthcare providers, Halcyon 2.0 is capable of kV CBCT images in approximately 15 seconds. This enhanced imaging capability helps ensure proper patient positioning while also accelerating the treatment workflow.
"We have been very happy with the strong positive response Halcyon has received from the global cancer care community," said Kolleen Kennedy, president of Varian's Oncology Systems business. "By working closely with our clinical partners, we have been able to quickly evolve the Halcyon system with these new imaging technologies, provide a pathway to adaptive radiotherapy and continue our efforts of advancing high-quality and cost-effective cancer care worldwide."
Halcyon provides highly targeted radiotherapy on a platform that's intuitive for clinicians and comfortable for patients. The streamlined workflow requires only nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. Halcyon is well suited to handle the majority of cancer patients, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer.
Halcyon 2.0 is currently Works in Progress and not available for sale. For more information on Halcyon, visit www.varian.com/halcyon.
About Varian Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Mark PlungyDirector, Public Relations+1 (650) 424-5630 firstname.lastname@example.org
Investor Relations Contact
J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 email@example.com
View original content:http://www.prnewswire.com/news-releases/varian-expands-capabilities-of-halcyon-treatment-system-with-new-imaging-technologies-300632630.html
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All